Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label Expanded Access Protocol for Esketamine Treatment of Subjects With Treatment Resistant Depression (TRD) Who do Not Have Other Treatment Alternatives

NCT04476446 is registered in ClinicalTrials.gov with Janssen-Cilag, S.A. as lead sponsor.

NCT NCT04476446
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04476446 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label Expanded Access Protocol for Esketamine Treatment of Subjects With Treatment Resistant Depression (TRD) Who do Not Have Other Treatment Alternatives
Lead sponsor
Janssen-Cilag, S.A.
Phase
Phase 3
Overall status
Completed
Start date
September 8, 2020
Completion date
June 16, 2023
Enrollment
41 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

depression